Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx, Active Motif Sign Global Sales, Distribution Agreement

NEW YORK (GenomeWeb) – VolitionRx announced today that it has signed a global sales and distribution agreement with Active Motif for a set of research-use-only kits, based on VolitionRx's Nucleosomics technology.

VolitionRx's RUO kits are based on the same Nu.Q immunoassay technology as the firm's cancer screening panels, and may be useful for exploring clinical questions beyond cancer biomarkers, the company said.

Researchers will be able to examine patterns of epigenetic modifications in circulating nucleosomes in diseases models, preclinical testing, and clinical trials. Potential clinical applications include cancer, inflammatory and infectious disease, and trauma patterns.

"These RUO kits will provide researchers ... with a new way to explore epigenetic modifications in circulating cell-free nucleosomes across different targets," Active Motif Founder and Chairman Joseph Fernandez said in a statement.

The companies previously signed a deal in 2013 to distribute VolitionRx's Nu.Q product line in Europe, the US, and Japan.

The new agreement is expected to will provide VolitionRx with "an additional revenue stream beyond ... the expected commercialization of our blood-based tests for cancer," VolitionRx CEO Cameron Reynolds said in a statement. "If the assays are developed as a companion diagnostic for another company's therapeutic, this could also potentially result in further future revenue through a licensing or similar arrangement."

In August, VolitionRx inked a deal with the Technical University of Munich to validate its technology and secure cancer trials.